Free Newsletter
Pfizer plots spinoff of Japanese R&D
Saved by the spinoff. Pfizer is looking to set up its Japanese R&D operation, previously slated for shutdown, as an independent company--with the help of a few investors, of course. The company may retain an equity stake in the lab, which focuses on developing pain relievers and digestive remedies.
Apparently Pfizer's close involvement in the spun-off lab is a sticking point with the potential investors--some want it, and some think the lab would be better off if it's more independent.
- read this piece from CNNMoney
Related Articles:
Pfizer honcho details plans to boost sales. Report
Pfizer's future rests with biotech. Report
Pfizer goes public with R&D pipeline. Report
Troubled Pfizer blueprints biotech venture effort. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: